Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Eli Lilly and Company recently completed ...

HOUSTON, TX and SUNSHINE COAST, QUEENSLAND / ACCESS Newswire / October 6, 2025 / BrYet US, Inc. (“BrYet”), a biotechnology innovator developing a drug with the potential to be a first-in-class ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 ...

The latest announcement is out from Adicet Bio ( (ACET) ).

Monte Rosa Therapeutics, Inc. has initiated a Phase 1 study for MRT-8102, a novel molecular glue degrader targeting the NEK7 protein to treat inflammatory conditions linked to the NLRP3 inflammasome.

Company will host an R&D investor webcast on Monday, June 2, at 11:00 am CDT to review updated RAMP 205 data as well as updated data on GFH375 presented at the ASCO 2025 Annual Meeting GenFleet ...

Data presented on September 17 at the 2025 Immunorad Conference PARIS and CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company ’’), a ...

Study investigator of Phase 1 trial presented poster at Society of Hematologic Oncology 13 th annual conference highlighting original study protocol SOUTH SAN FRANSCISCO, Calif., Sept. 08, 2025 (GLOBE ...

Monotherapy of envafolimab in patients with high tumor mutational burden advanced solid tumors: Results from a phase II clinical trial. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Targeting Phase 1 commissioning by the end of 2026 HIGHLIGHTS Existing fully permitted Central Gawler Mill adjacent to brownfield Challenger mines Challenger JORC (2012) Mineral Resources Estimate now ...

Purpose of Study: The purpose of this study is to establish the safety and potential effectiveness of investigational FT819 in participants with moderate to severe systemic lupus erythematosus (SLE) ...